Bristol-Myers Squibb Reports Second Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
July 27, 2018 8:21 AM EDTBMO Capital raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $51.00) while maintaining a Market Perform rating.
Analyst Alex Arfaei commented, "Bristol had a good 2Q but expectations had risen, which, coupled with untimely (CHMP RCC) news, pressured BMY. The... More
Bristol-Myers Squibb (BMY) Tops Q2 EPS by 14c; Raises Outlook
July 26, 2018 7:01 AM EDTBristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $1.01, $0.14 better than the analyst estimate of $0.87. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.48 billion.
We had a very good second quarter where we delivered strong performance for Eliquis and... More
